Revised Geneva Score Calculator for Pulmonary Embolism

What is the Revised Geneva Score?

The Revised Geneva Score is a standardized clinical decision rule designed to assess the pre-test clinical probability of acute Pulmonary Embolism (PE) in adult patients presenting with suspected venous thromboembolism. Developed by Dr. Grégoire Le Gal and colleagues in 2006 (published in the Annals of Internal Medicine) and later updated with a Simplified Revised Geneva Score by Dr. F.A. Klok and associates in 2008 (Archives of Internal Medicine), the scoring system is widely recommended by the European Society of Cardiology (ESC) and American College of Chest Physicians (ACCP).

Key Advantages of the Revised Geneva Score

Unlike the Wells Criteria for PE which includes a subjective criterion ("an alternative diagnosis is less likely than PE"), the Revised Geneva Score is entirely composed of objective clinical variables obtained from patient history, physical examination, and basic vital signs. This eliminates inter-observer variability between emergency physicians and trainees.

Predictor Variables and Point Scoring

The table below outlines the 8 clinical criteria and their point allocations in both the Original Revised and Simplified models:

Clinical Predictor	Original Revised Points	Simplified Points
Age > 65 years	+1 point	+1 point
Previous Deep Vein Thrombosis (DVT) or PE	+3 points	+1 point
Surgery under general anesthesia or lower limb fracture in past month	+2 points	+1 point
Active malignant condition (solid or hematologic, active or <1 yr)	+2 points	+1 point
Unilateral lower-limb pain	+3 points	+1 point
Hemoptysis (coughing up blood)	+2 points	+1 point
Pain on lower-limb deep venous palpation AND unilateral edema	+4 points	+1 point
Heart rate: 75 to 94 beats per minute	+3 points	+1 point
Heart rate: ≥ 95 beats per minute	+5 points	+2 points

Risk Stratification & Clinical Interpretation

The total score is interpreted using either a 3-tier model or a 2-tier (dichotomous) model:

3-Level Probability Model

Low Clinical Probability (Original: 0 to 3 points | Simplified: 0 to 1 point): Observed PE prevalence is approximately 8% to 10%. Initial diagnostic testing with a high-sensitivity D-dimer assay is recommended. A negative D-dimer (< 500 μg/L or age-adjusted cutoff) safely rules out PE without the need for radiation exposure or intravenous contrast.
Intermediate Clinical Probability (Original: 4 to 10 points | Simplified: 2 to 4 points): Observed PE prevalence is approximately 28% to 30%. High-sensitivity D-dimer testing should be obtained; if positive, proceed to computed tomographic pulmonary angiography (CTPA).
High Clinical Probability (Original: ≥ 11 points | Simplified: ≥ 5 points): Observed PE prevalence is 65% to 74%. Patients should undergo direct diagnostic imaging (CTPA or ventilation-perfusion V/Q scan). D-dimer testing is not recommended because a normal result cannot safely rule out PE in high-prevalence settings.

2-Level (Dichotomous) Model

PE Unlikely (Original: 0 to 5 points | Simplified: 0 to 2 points): Prevalence ~12%. Order D-dimer to rule out PE.
PE Likely (Original: ≥ 6 points | Simplified: ≥ 3 points): Prevalence ~64%. Proceed immediately to CTPA imaging.

Explore Related Clinical Risk Tools

Evaluate venous thromboembolism risk in hospitalized medical patients with the Padua Score Calculator, assess oxygenation impairment with the PaO2 FiO2 Ratio Calculator, or review perioperative risks using the Revised Cardiac Risk Index Calculator.

Frequently Asked Questions

How does the Revised Geneva Score differ from the Wells Criteria for PE?

The Wells Score includes a subjective assessment ("PE is #1 diagnosis or equally likely", worth 3 points), which can lead to variance among clinicians. The Revised Geneva Score relies strictly on standardized, objective clinical variables, offering consistent reproducibility.

Can D-dimer testing rule out pulmonary embolism in high-risk patients?

No. In patients categorized as High Probability (score ≥ 11 in original or ≥ 5 in simplified), false-negative D-dimer rates are unacceptable. High-risk patients require definitive pulmonary vascular imaging (CTPA or V/Q scan).

What is the age-adjusted D-dimer cutoff?

For patients older than 50 years with low or intermediate clinical probability, guidelines support using an age-adjusted cutoff calculated as: Age × 10 μg/L (FEU), which increases diagnostic specificity without compromising sensitivity.

When is a V/Q lung scan preferred over CT Pulmonary Angiography (CTPA)?

A ventilation-perfusion (V/Q) scan is preferred in patients with severe renal impairment (eGFR < 30 mL/min), documented severe iodinated contrast allergy, or pregnant patients when chest radiographs are normal.

Is the Simplified Revised Geneva Score as accurate as the original model?

Yes. Multiple large prospective validation trials (including the ADJUST-PE and PROPER studies) demonstrated that the Simplified Revised Geneva Score achieves equivalent diagnostic safety and clinical utility compared to the original weighted version.

Report

Revised Geneva Score Calculator